Company Profile

Targeted Molecules Corporation
Profile last edited on: 9/16/2008      CAGE:       UEI:

Business Identifier: Targeted drug therapies using a proprietary in vivo drug discovery platform.
Year Founded
2000
First Award
2001
Latest Award
2006
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3030 Bunker Hill Street Suite 318
San Diego, CA 92109
   (858) 777-2800
   N/A
   www.targetedmolecules.com
Location: Single
Congr. District: 50
County: San Diego

Public Profile

During 2005 Targeted Molecules Corporation was acquired by Chromos. Targeted Molecules Corporation (TMC) exploits a unique technology platform, in vivo screening of phage combinatorial libraries for peptides that home selectively to specific tissues or sites of disease. Targeted Molecules is a developer of novel antibody therapeutics in the validated class of drugs known as Selective Adhesion Molecule Inhibitors (SAMI). The company is currently focused on the advancement of two SAMI antibodies that address unmet medical needs in the areas of chronic inflammation and acute thrombosis.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 1 NIH $139,050
Project Title: A platelet ligand mimetic for neurothrombotic disorders
2001 1 NIH $100,000
Project Title: Novel prostate homing peptides as potential diagnostics

Key People / Management

  Elias Lazarides -- President

  Paul Cayer -- CFO & SVP, Business Development

  Catherine M Woods -- Executive Director, Biological Research & Extramural Affairs

Company News

There are no news available.